All
Dacomitinib Shows Promising Activity in EGFR-Mutated and HER2-Mutated NSCLC
Nearly three-fourths of patients with previously untreated advanced NSCLC with specific mutations of EGFR experienced one full year of PFS when given the investigational therapeutic agent dacomitinib.
